• Evaluating Project Optimus implications for DDR programs and how proactive pharmacological modeling accelerates clinical success

• Highlighting the challenges of dose selection in DDR inhibitor combinations, balancing efficacy with tolerability

• Showcasing how model-based drug development leverages preclinical and clinical data to guide smarter escalation and expansion strategies